2020-Positive-business-momentum-despite-COVID-19-impact

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19  Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus  Overall R&D investment up 7% to 3.7 billion EUR in 2020 (18.9% of net sales)  Outlook 2021: slight year-on-year increase in net sales on a comparable basis  

Source: Boehringer Ingelheim Corporate News - March 23, 2021 Category: Research Source Type: news